Ordering Recommendation

• Monitor disease in patient previously diagnosed with pemphigoid and increased antibodies for IgG BP 180 and/or BP 230; IgG BP 180 antibody levels correlate with disease activity. 
• For initial diagnosis and assessment of disease progression or changes, the preferred test is Basement Membrane Zone Antibody Panel (3001410), or Immunobullous Disease Panel, Epithelial (3001409). 
• Epithelial Basement Membrane Zone Antibody IgG (0092056) can be used to determine the involvement of IgG BMZ antibodies and pattern of reactivity on split skin substrate. Also consider other types of BMZ antibody-associated disease testing, (ie, Epithelial Basement Membrane Zone Antibody IgA (0092057), Collagen Type VII Antibody IgG by ELISA (2010905), or Herpes Gestationis Factor (Complement-Fixing Basement Membrane Zone Antibody IgG) (0092283)).

BP180 230G

Enzyme-Linked Immunosorbent Assay




3-11 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation

Plain red or serum separator tube (SST).

Specimen Preparation

Transfer 2 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)

Storage/Transport Temperature


Unacceptable Conditions

Hemolyzed or lipemic specimens.


Ambient: 1 week; Refrigerated: 2 weeks; Frozen: Indefinitely

Reference Interval

By report

Interpretive Data

No compliance statements are in use for this test.


For specimens less than 0.5 mL, call the Immunodermatology Laboratory at (866) 266-5699.

Hotline History
CPT Codes

83516 x2

Component Test Code* Component Chart Name LOINC
0092568 Bullous Pemphigoid Antigens, IgG 57911-0
2010915 EER Bullous Pemphigoid Antigens, IgG
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • BP 180 and BP 230
  • BP Antigen 1
  • BP Antigen 2
Bullous Pemphigoid Antigens (180 kDa and 230 kDa), IgG